A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Crossref DOI link: https://doi.org/10.1007/s12325-020-01397-9
Published Online: 2020-06-10
Published Print: 2020-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Jie
Li, Junlong
Ma, Qiufei
Yang, Hongbo
Signorovitch, James
Wu, Eric
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Text and Data Mining valid from 2020-06-10
Version of Record valid from 2020-06-10
Article History
Received: 6 May 2020
First Online: 10 June 2020